# ApiFix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apifix

- Industry: Medical Devices & Equipment
- Headquarters: Israel
- Website: www.apifix.com
- Total disclosed funding: $5M
- Latest round: Series B (Nov 29, 2016)
- Investors on record: 2

## About

ApiFix Ltd. is a medical technology company focused on providing less invasive treatment options for adolescent idiopathic scoliosis (AIS), specifically through their innovative ApiFix® procedure.Founded in 2011 and headquartered in Israel, ApiFix Ltd. specializes in treating adolescent idiopathic scoliosis. The company was acquired by OrthoPediatrics Corp. in April 2020 for USD 67 mn. The acquisition marked a significant shift in its operational strategy, aligning with OrthoPediatrics’ focus on pediatric orthopedic solutions.ApiFix Ltd. specializes in innovative treatment options for adolescent idiopathic scoliosis (AIS), with their core offering being the ApiFix® procedure. This less invasive procedure is designed for select AIS patients with flexible, single curves measuring between 35 and 60 degrees, providing a motion-preserving alternative to traditional bracing and spinal fusion. The procedure aims to correct spinal curvature effectively while avoiding the long-term implications associated with fusion, thus addressing a significant gap in treatment options for patients whose curves are progressive and unresponsive to bracing. ApiFix serves a range of stakeholders in the healthcare sector, including orthopedic surgeons and pediatric specialists, catering primarily to adolescent patients experiencing scoliosis, with a focus on markets in the United States and other international regions where specialized spinal treatments are in demand.ApiFix Ltd. generates revenue through its proprietary medical procedure, the ApiFix® treatment, classified as a humanitarian use device authorized for sale only through physicians. The transaction structure primarily involves B2B interactions, where healthcare providers purchase the device and related services directly from ApiFix or its parent company, OrthoPediatrics Corp. The pricing strategy includes costs associated with the device itself, as well as potential ancillary services linked to its application in clinical settings, occurring within a framework of healthcare reimbursement models that may involve insurance providers.ApiFix Ltd. plans to leverage its recent acquisition by OrthoPediatrics Corp. to drive growth by expanding its product offerings and entering new markets. The company aims to enhance its portfolio of less invasive scoliosis treatment options in the upcoming years. Following the acquisition deal in April 2020, ApiFix will utilize the USD 67 mn to support product development and expand its reach, particularly in the U.S. and other international markets with growing demand for specialized spinal treatments.

## Funding rounds

- Series B, Nov 29, 2016, $5M — Trendlines Group, Aesculap, Inc.
- Series B, Oct 22, 2013 — Trendlines Group

## Investors

- Trendlines Group (https://capitalatlas.ai/funds/trendlines-group) — Series B
- Aesculap, Inc. — Series B